Mylan Gets Favorable Appeals Court Ruling in Patent Dispute Over Teva's Copaxone
October 12 2018 - 1:30PM
Dow Jones News
By Josh Beckerman
Mylan NV (MYL) said a federal appeals court affirmed prior
decisions in the company's favor in a patent dispute with Teva
Pharmaceutical Industries Ltd. (TEVA).
Last year, Mylan received U.S. Food and Drug Administration
approval to sell glatiramer acetate injection, a generic version of
Teva's blockbuster Copaxone drug, which treats multiple
sclerosis.
Mylan said the appeals court affirmed that Teva's 40 mg/ML
dosing patents are invalid.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 12, 2018 13:15 ET (17:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024
